A Positive Trial

Genentech's Lucentis helps prevent vision loss due to diabetic macular edema, a phase three clinical trial sponsored by the National Eye Institute found. The trial, which included 691 patients or 854 eyes (as not everyone had both eyes treated), found that 3 to 4 percent of Lucentis-treated eyes had visual loss after the one year while 13 percent of those treated with lasers did, reports the New York Times.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.